Surrozen reports full-year 2021 net loss of $47.3M; on track for Phase 1 starts in Q3 2022

Surrozen, Inc./DE

FY2021 net loss $47.3M vs $20.4M in 2020; R&D expenses $35.5M.
Cash and equivalents $137.8M as of Dec 31, 2021.
Phase 1 trials for SZN-1326 (ulcerative colitis) and SZN-043 (alcoholic hepatitis) expected to start Q3 2022.
Nominated SZN-413, a Fzd4 bi-specific antibody, for retinal vascular diseases including wet AMD.
2022 Annual Meeting set for June 7, 2022; record date April 11, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.